Eli Lilly (LLY) PT Lowered to $78 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Eli Lilly (LLY) PT Raised to $82 at Credit Suisse
April 25, 2018 8:59 AM EDTCredit Suisse raised its price target on Eli Lilly (NYSE: LLY) to $82.00 (from $80.00) while maintaining a Underperform rating.
... MoreEli Lilly (LLY) PT Raised to $100 at Berenberg
April 25, 2018 6:06 AM EDTBerenberg raised its price target on Eli Lilly (NYSE: LLY) to $100.00 (from $99.00) while maintaining a Buy rating.
... MoreEli Lilly (LLY) PT Raised to $95 at Deutsche Bank
April 25, 2018 4:58 AM EDTDeutsche Bank raised its price target on Eli Lilly (NYSE: LLY) to $95.00 (from $94.00) while maintaining a Buy rating.
... MoreEli Lilly (LLY) PT Maintained at $95 at Cowen on 1Q18 Report; 'Top & Bottom Line Beat... FY18 Guidance Raised'
April 24, 2018 11:50 AM EDTCowen maintained its price target on Eli Lilly (NYSE: LLY) at $95.00 while maintaining a Outperform rating, following the company's first quarter earnings report.
Analyst Steve Scala notes an upbeat outlook on the shares, as LLY reported first quarter sales and earnings per share results above... More
Eli Lilly & Co. (LLY) Tops Q1 EPS by 21c, Raises FY EPS Guidance
April 24, 2018 6:27 AM EDTEli Lilly & Co. (NYSE: LLY) reported Q1 EPS of $1.34, $0.21 better than the analyst estimate of $1.13. Revenue for the quarter came in at $5.7 billion versus the consensus estimate of $5.49 billion.
GUIDANCE:
Eli Lilly & Co. sees FY2018 EPS of $5.10-$5.20, versus the... More
